[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617347":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":53,"collaborators":11,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":11,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":11,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":11,"overallStatus":74,"whyStopped":11,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"60 children with community acquired pneumonia will receive oral coenzymeQ10","EXPERIMENTAL",null,[13],"Drug: oral coenzymeQ10",{"label":15,"type":16,"description":11,"interventionNames":11},"60 children with community acquired pneumonia with the standard pneumonia treatment.","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","oral coenzymeQ10","60 children with community acquired pneumonia will receive oral coenzymeQ10 in capsule form at a dose of 100-200 mg\u002Fkg\u002Fday, as adjunct therapy to the usual pneumonia treatment till the recovery of the disease.",[9],[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Ahmed Elniny Lecturer of Pediatrics, MD","CONTACT","01002219783","Ahmedelniny8@gmail.com",[30],{"facility":5,"status":11,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Tanta","Gharbia Governorate","37515","Egypt","EG",{"type":37,"coordinates":38},"Point",[39,40],31.00192,30.78847,{"lat":40,"lon":39},[43,46,47,50],{"name":44,"role":26,"phone":45,"phoneExt":11,"email":11},"Rehab Zaki Elmeazawy","01004815280",{"name":11,"role":26,"phone":11,"phoneExt":11,"email":28},{"name":48,"role":49,"phone":11,"phoneExt":11,"email":11},"Rehab Zaki Elmeazawy, MD","PRINCIPAL_INVESTIGATOR",{"name":51,"role":52,"phone":11,"phoneExt":11,"email":11},"Ahmed Elniny Ahmedelniny8@gmail.com, MD","SUB_INVESTIGATOR",{"type":49,"investigatorFullName":44,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Lecturer of pediatrics","100617347","coenzyme-q10-in-pediatric-community-acquired-pneumonia-100617347",false,"NCT07317440","Coenzyme Q10 in Pediatric Community-Acquired Pneumonia","Coenzyme Q10 as an Adjunct Therapy in Pediatric Community-Acquired Pneumonia","Inclusion Criteria:\n\n* All children aged 2 months -18 years with community acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x ray indicating community acquired pneumonia\n\nExclusion Criteria:\n\n* Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorder impacting respiration i.e. genetic, metabolic, neuromuscular disorders, children with CHD affecting the pulmonary blood flow.","ALL","2 Months","18 Years",{"count":66,"type":67},120,"ESTIMATED","INTERVENTIONAL",[70],"NA","The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia",[73],"Community Acquired Pneumonia","NOT_YET_RECRUITING","2025-12-18",{"date":77,"type":78},"2026-01-05","ACTUAL",{"date":80,"type":67},"2025-12-31",{"date":82,"type":67},"2026-12-31",{"name":5,"class":6},1]